<DOC>
	<DOCNO>NCT00290433</DOCNO>
	<brief_summary>The goal clinical research study learn treatment two type chemotherapy combination help control peripheral T-cell lymphoma .</brief_summary>
	<brief_title>Efficacy HCVIDDOXIL Regimen Patients With Newly Diagnosed Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>All drug use study commonly use treatment cancer . However , use drug combination investigational . During treatment , give two different cycle chemotherapy , alternate every 21 day . For Cycle 1 , cyclophosphamide give vein two time day Days 1,2 , 3 . Each dose take around 3 hour give . Mesna give vein nonstop Days 1 3 . Pegylated liposomal doxorubicin give vein 1 hour Day 2 . Vincristine give vein Days 4 11 . Dexamethasone give mouth Days 1 4 11 14 . Other drug give , , chemotherapy help decrease risk develop side effect . These drug may give mouth injection . For Cycle 2 , methotrexate give vein 2 hour Day 1 22 hour day 1 . Cytarabine give vein twice day Days 2 3 . Each dose take 2 hour give . Other drug give , , treatment help decrease risk develop side effect . These drug may give mouth injection . To help increase blood count help decrease risk develop infection , doctor may decide treatment filgrastim necessary . Filgrastim may give once-a-day injection skin start 24 hour end Day 4 vincristine ( Cycle 1 ) start 24 hour end Cytarabine ( Cycle 2 ) . Your blood count monitor filgrastim stopped level become normal . Cycles 1 2 alternate every 21 day . Both Cycles 1 2 give outpatient basis physician authorizes . However , serum creatinine ( blood test ) reach certain level , Cycle 2 give inpatient basis . Depending disease responds , treatment may stop 2,4 , 6 cycle . However , treatment may continue 8 cycle . During treatment , around 2-3 tablespoon blood collect least week routine test . After every 2 cycle , tumor measure use x-rays scan ( CT , MRI , etc . ) bone marrow sample take . Heart scan heart function test may also need doctor feel necessary . If disease get bad experience intolerable side effect , take study doctor discus treatment option . After last cycle chemotherapy , follow-up exam schedule . During exam , chest x-ray CT scan chest , abdomen ( stomach ) pelvis ( waist area ) , PET scan . You blood collect ( 2-3 tablespoon ) routine test . If doctor feel necessary , may also sample bone marrow collect . You may choose long-term follow-up exam M. D. Anderson local physician . This investigational study . All study drug approve FDA cancer treatment commercially available . However , use drug combination experimental . Up 55 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Confirmed diagnosis previously untreated Tcell Non Hodgkin 's Lymphomas NK lymphoma , exception cluster differentiation antigen 30 ( CD30+ ) alk1+ Tanaplastic large cell lymphoma ( ALCL ) . Patients skin involvement alone also exclude . For patient skin involvement part systemic disease , prior topical treatment allow . 2 . Patients performance status 3 less ( Zubrod Scale see Appendix D ) . 3 . Serum bilirubin &lt; /= 1.5 mg/dl serum creatinine &lt; /= 2.0 mg/dl unless due lymphoma ; Absolute neutrophil count ( ANC ) &gt; /= 1000 mm^3 platelet &gt; /= 100,000 mm^3 unless due lymphoma . 4 . Cardiac ejection fraction 50 % great multigated radionuclide angiography ( MUGA ) echocardiogram . 5 . Ages 18 old . 6 . Patients must willing receive transfusion blood product . 1 . Patients CD30+ alk1+ Tanaplastic large cell lymphoma ( ALCL ) patient skin involvement alone . 2 . Pregnancy 3 . HIV positive serology 4 . Central nervous system ( CNS ) involvement 5 . Comorbid medical , Child 's Class C liver cirrhosis , endstage renal disease , symptomatic congestive heart failure , psychiatric illness preclude treatment intense dose chemotherapy determine primary investigator 6 . Concurrent previous malignancy whose prognosis poor ( &lt; 90 % probability survival 5 year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Peripheral T Cell</keyword>
	<keyword>HCVIDDOXIL Regimen</keyword>
	<keyword>ARA-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>Doxorubicin hydrochloride</keyword>
	<keyword>Doxil</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Mesna</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Vincristine</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>